UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of adverse events associated with idelalisib treatment: expert panel opinion

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2779-2786

2015

Volltextzugriff (PDF)

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Oncotarget, 2018-04, Vol.9 (31), p.21820-21830

2018

Volltextzugriff (PDF)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)

Clinical microbiology and infection, 2018-06, Vol.24, p.S53-S70

2018

Volltextzugriff (PDF)

Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients

British journal of haematology, 2022-11, Vol.199 (3), p.339-343

2022

Volltextzugriff (PDF)

Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells

International journal of pharmaceutics, 2024-05, Vol.657, p.124144-124144, Article 124144

2024

Volltextzugriff (PDF)

Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy

Investigative ophthalmology & visual science, 2018-09, Vol.59 (11), p.4477-4485

2018

Volltextzugriff (PDF)

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8 + T Cells

Frontiers in immunology, 2017-09, Vol.8, p.1221-1221

2017

Volltextzugriff (PDF)

Mature Follow-up from a Phase-2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Acta haematologica polonica, 2015-09, Vol.46, p.48-49

2015

Volltextzugriff (PDF)

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

Nature reviews. Cancer, 2018-03, Vol.18 (3), p.148-167

2018

Volltextzugriff (PDF)

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

Critical reviews in oncology/hematology, 2022-08, Vol.176, p.103749-103749, Article 103749

2022

Volltextzugriff (PDF)

The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis

European journal of pharmacology, 2024-11, Vol.983, p.176952, Article 176952

2024

Volltextzugriff (PDF)

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Annals of oncology, 2017-05, Vol.28 (5), p.1050-1056

2017

Volltextzugriff (PDF)

PIK3C[delta] expression by fibroblasts promotes triple-negative breast cancer progression

The Journal of clinical investigation, 2020-06, Vol.130 (6), p.3188

2020

Volltextzugriff (PDF)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells

Oncotarget, 2017-01, Vol.8 (4), p.6102-6113

2017

Volltextzugriff (PDF)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

Frontiers in immunology, 2021-03, Vol.12, p.608625-608625

2021

Volltextzugriff (PDF)

Pulmonary adverse events related to idelalisib therapy: A single centre experience

Journal of chemotherapy (Florence), 2018-09, Vol.30 (5), p.318-322

2018

Volltextzugriff (PDF)

Results of a multicentre UK‐wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

British journal of haematology, 2018-05, Vol.181 (4), p.555-559

2018

Volltextzugriff (PDF)

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

Frontiers in pharmacology, 2024-02, Vol.15, p.1337436-1337436

De, Surya K

2024

Volltextzugriff (PDF)

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials

British journal of haematology, 2021-02, Vol.192 (4), p.720-728

2021

Volltextzugriff (PDF)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

Annals of hematology, 2023-11, Vol.102 (11), p.3083-3090

2023

Volltextzugriff (PDF)

Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes

Experimental eye research, 2020-01, Vol.190, p.107884-107884, Article 107884

2020

Volltextzugriff (PDF)

Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis

Expert review of clinical pharmacology, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-9

2023

Volltextzugriff (PDF)

Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach

Toxicological sciences, 2019-12, Vol.172 (2), p.265-278

2019

Volltextzugriff (PDF)

B-cell receptor signaling as a driver of lymphoma development and evolution

Seminars in cancer biology, 2013-12, Vol.23 (6), p.410-421

2013

Volltextzugriff (PDF)

Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia

Expert opinion on drug metabolism & toxicology, 2023-09, Vol.19 (9), p.617-633

2023

Volltextzugriff (PDF)

1 – 25 von 342

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(268)
Mit Volltextzugriff
(230)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Idelalisib
(329)
Science & Technology
(254)
Life Sciences & Biomedicine
(248)
Humans
(151)
Ibrutinib
(146)
Oncology
(130)
Chronic Lymphocytic Leukemia
(123)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(80)
Hematology
(77)
Venetoclax
(67)
Leukemia
(61)
Pharmacology & Pharmacy
(52)
Antineoplastic Agents - Therapeutic Use
(49)
Lymphoma
(46)
Obinutuzumab
(39)
Antineoplastic Agents - Pharmacology
(36)
Quinazolinones - Therapeutic Use
(35)
Treatment Outcome
(35)
Male
(34)
Patients
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

British Journal Of Haematology
(14)
M2 Presswire
(14)
Pr Newswire
(14)
Business Wire
(11)
Leukemia & Lymphoma
(11)
Cancers
(9)
Oncotarget
(8)
Medicina Clínica
(7)
Memo - Magazine Of European Medical Oncology
(7)
Current Hematologic Malignancy Reports
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Management of adverse events associated with idelalisib treatment: expert panel opinion

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)

Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients

Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells

Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8 + T Cells

Mature Follow-up from a Phase-2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

PIK3C[delta] expression by fibroblasts promotes triple-negative breast cancer progression

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

Pulmonary adverse events related to idelalisib therapy: A single centre experience

Results of a multicentre UK‐wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes

Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis

Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach

B-cell receptor signaling as a driver of lymphoma development and evolution

Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia

Suchergebnisse filtern